HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia.
- Author:
Hui LIU
1
;
Wen-Bin QIAN
;
Wen-Yuan MAI
;
Hai-Tao MENG
;
Hong-Yan TONG
;
Yin TONG
;
Li-Ping MAO
;
Jian HUANG
;
Lei WANG
;
Dao-Zi JIANG
;
Jie JIN
Author Information
- Publication Type:Journal Article
- MeSH: Aclarubicin; administration & dosage; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Cytarabine; administration & dosage; Female; Harringtonines; administration & dosage; Humans; Leukemia, Myeloid, Acute; drug therapy; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult
- From: Chinese Journal of Hematology 2008;29(1):9-12
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyse the outcome of newly diagnosed adult acute myeloid leukemia (AML) patients treated with HAA (homoharringtonine, cytarabine and aclarubicin) regimen and explore the efficacy and safety of this regimen.
METHODSEighty patients were treated with HAA regimen. The complete remission (CR) rate was observed. Kaplan-Meier method was used to estimate relapse free survival (RFS) rate and the differences were compared with 2-sided log-rank test.
RESULTSOf the 80 patients, 65 (81%) attained CR and the CR rate after the first course of induction was 75%. For the CR patients, the median follow-up was 26 (2 -69) months, and the estimated 3-year overall survival (OS) rate was 51% and the estimated 3-year RFS was 53%. For the AML-M5 and AML-M /M2 patients the CR rate was 74% and 87% and 3 year RFS of CR patients was 75% and 37%, respectively. The CR rate of 100%, 83% and 20% was achieved in patients with favorable, intermediate and unfavorable cytogenetics, respectively. The 3 year OS for favorable and intermediate group was 76% and 50% respectively. The median survival time of unfavorable group was only 6 months.
CONCLUSIONHAA regimen is a safe, efficacious, and well-tolerable induction therapy for newly diagnosed AML.
